UTime shares surge 22.55% after-hours on $10M smart health device deal with Tumu Vertex.
ByAinvest
Wednesday, Dec 31, 2025 4:39 pm ET1min read
WTO--
UTime Limited (NASDAQ:WTO) surged 22.55% in after-hours trading following the announcement of a $10 million procurement agreement with Denver-based Tumu Vertex LLC for 50,000 smart health devices, including blood pressure watches and ECG smart rings. The deal, marking UTime’s entry into the North American medical-grade wearable market, includes phased deliveries starting in early 2026 and joint quality control protocols. UTime’s CEO emphasized the strategic significance of the partnership, highlighting its potential to accelerate next-generation health monitoring technology development. The agreement aligns with growing demand for continuous health solutions and underscores UTime’s expansion into high-margin medical tech, bolstering investor confidence in its long-term growth prospects.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet